Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma Article

Bell, Erica H, Zhang, Peixin, Shaw, Edward G et al. (2020). Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma . JOURNAL OF CLINICAL ONCOLOGY, 38(29), 10.1200/JCO.19.02983

Open Access International Collaboration

cited authors

  • Bell, Erica H; Zhang, Peixin; Shaw, Edward G; Buckner, Jan C; Barger, Geoffrey R; Bullard, Dennis E; Mehta, Minesh P; Gilbert, Mark R; Brown, Paul D; Stelzer, Keith J; McElroy, Joseph P; Fleming, Jessica I; Timmers, Cynthia D; Becker, Aline P; Salavaggione, Andrea L; Liu, Ziyan; Aldape, Kenneth; Brachman, David G; Gertler, Stanley Z; Murtha, Albert D; Schultz, Christopher J; Johnson, David; Laack, Nadia N; Hunter, Grant K; Crocker, Ian R; Won, Minhee; Chakravarti, Arnab

sustainable development goals

authors

publication date

  • October 10, 2020

webpage

published in

keywords

  • ATRX
  • CHEMOTHERAPY
  • IDH
  • Life Sciences & Biomedicine
  • MOLECULAR CLASSIFICATION
  • MUTATIONS
  • OLIGODENDROGLIOMA
  • Oncology
  • Science & Technology
  • TUMORS

Digital Object Identifier (DOI)

publisher

  • AMER SOC CLINICAL ONCOLOGY

volume

  • 38

issue

  • 29